Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer

被引:63
作者
Loubinoux, I
Tombari, D
Pariente, J
Gerdelat-Mas, A
Franceries, X
Cassol, E
Rascol, O
Pastor, J
Chollet, F
机构
[1] Hop Purpan, INSERM, U455, F-31059 Toulouse, France
[2] Hop Purpan, Dept Neurol, F-31059 Toulouse, France
[3] Hop Purpan, Dept Neuroradiol, F-31059 Toulouse, France
[4] Hop Purpan, Ctr Clin Invest, F-31059 Toulouse, France
关键词
fMRI motor performance; automatism; SSRI; chronic treatment;
D O I
10.1016/j.neuroimage.2004.12.023
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
SSRIs are postulated to modulate motor behavior. A single dose of selective serotoninergic reuptake inhibitors (SSRIs) like fluoxetine, paroxetine, or fluvoxamine, has been shown to improve motor performance and efficiency of information processing for simple sensorimotor tasks in healthy subjects. At a cortical level, a single dose of SSRI was shown to induce a hyperactivation of the primary sensorimotor cortex (S1M1) involved in the movement (Loubinoux, L, Boulanouar, K., Ranjeva, J. P., Carel, C., Berry, I., Rascol, O., Celsis, P., and Chollet, F., 1999. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J. Cereb. Blood Flow Metab. 19 1365-1375, Loubinoux, I., Pariente, J., Boulanouar, K., Carel, C., Manelfe, C., Rascol, 0., Celsis, P., and Chollet, F., 2002. A Single Dose of Serotonin Neurotransmission Agonist Paroxetine Enhances Motor Output. A double-blind, placebo-controlled, fMRI study in healthy subjects. NeuroImage 15 26-36). Since SSRIs are usually given for several weeks, we assessed the behavioral and cerebral effects of a one-month chronic administration of paroxetine on a larger group. In a double-blind, placebo controlled and crossover study, 19 subjects received daily 20 mg paroxetine or placebo, respectively, over a period of 30 days separated by a wash-out period of 3 months. After each period, the subjects underwent an fMRI (active or passive movement, dexterity task, sensory discrimination task) and a behavioral evaluation. Concurrently, a TMS (transcranial magnetic stimulation) study was conducted (Gerdelat-Mas, A., Loubinoux, I., Tombari, D., Rascol, 0., Chollet, F., Simonetta-Moreau, M., 2005. Chronic administration of selective serotonin re-uptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. NeuroImage 27, 314-322). Results: On the one hand, paroxetine improved motor performances at the finger tapping test (P = 0.02) without affecting choice reaction time, strength and dexterity significantly. Subjects were also faster in processing the spatial incongruency between a stimulus and the motor response (P = 0.04). In order to differentiate behavioral components, a principal component analysis was performed on all motor tests, and several characteristics were differentiated: strength, speed, skill, attention, and motor response coding. Paroxetine would improve the efficiency of motor response coding (MANOVA on the factors; factor 3, P = 0.01). On the other hand, the chronic administration induced a significant hypoactivation of S1M1 whatever the task: motor or sensory, simple or complex (random effect analysis, P < 0.05). The hypoactivation correlated with the improvement of performances at the finger tapping test (P < 0.05) suggesting more efficiency in cerebral motor processing. Conclusions: Our results showed a clear modulation of sensory and motor cerebral activation after a chronic paroxetine administration. An improvement in both behavior and cerebral efficiency was suggested. It could be hypothesized that monoamines, by an unspecific effect, may tune the response of pyramidal neurons to optimize performances. (c) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:299 / 313
页数:15
相关论文
共 66 条
[1]   A novel function for serotonin-mediated short-term facilitation in Aplysia:: Conversion of a transient, cell-wide homosynaptic Hebbian plasticity into a persistent, protein synthesis-independent synapse-specific enhancement [J].
Bailey, CH ;
Giustetto, M ;
Zhu, HX ;
Chen, M ;
Kandel, ER .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (21) :11581-11586
[2]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[3]   CHRONIC TREATMENT WITH FLUVOXAMINE INCREASES EXTRACELLULAR SEROTONIN IN FRONTAL-CORTEX BUT NOT IN RAPHE NUCLEI [J].
BEL, N ;
ARTIGAS, F .
SYNAPSE, 1993, 15 (03) :243-245
[4]   REPEATED TREATMENT WITH FLUOXETINE DECREASES THE NUMBER OF SPONTANEOUSLY ACTIVE-CELLS PER TRACK IN FRONTAL-CORTEX [J].
CECI, A ;
FODRITTO, F ;
BORSINI, F .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 271 (01) :231-234
[5]   QUANTITATIVE AUTORADIOGRAPHY OF H-3 PAROXETINE BINDING-SITES IN RAT-BRAIN [J].
CHEN, HT ;
CLARK, M ;
GOLDMAN, D .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1992, 27 (04) :209-216
[6]   FLUOXETINE EFFECTS ON CEREBRAL GLUCOSE-METABOLISM [J].
COOK, EH ;
METZ, J ;
LEVENTHAL, BL ;
LEBOVITZ, M ;
NATHAN, M ;
SEMERDJIAN, SA ;
BROWN, T ;
COOPER, MD .
NEUROREPORT, 1994, 5 (14) :1745-1748
[7]   FENFLURAMINE AND CEREBRAL GLUCOSE [J].
COOK, EH ;
METZ, J ;
COOPER, MD ;
CHOU, JS ;
LEVENTHAL, BL .
BIOLOGICAL PSYCHIATRY, 1992, 31 (11) :1173-1174
[8]   Bi-phasic change in BDNF gene expression following antidepressant drug treatment [J].
Coppell, AL ;
Pei, Q ;
Zetterström, TSC .
NEUROPHARMACOLOGY, 2003, 44 (07) :903-910
[9]   Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy [J].
Dam, M ;
Tonin, P ;
DeBoni, A ;
Pizzolato, G ;
Casson, S ;
Ermani, M ;
Freo, U ;
Piron, L ;
Battistin, L .
STROKE, 1996, 27 (07) :1211-1214
[10]   Contrasting effects of chronic paroxetine on 5-HT1A control of dorsal raphe cell firing and 5-HT release [J].
Davidson, C ;
Stamford, JA .
NEUROREPORT, 1998, 9 (11) :2535-2538